Nasdaq btai.

NEW HAVEN, Conn., Aug. 03, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop ...BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. The Company’s drug re-innovation ...BTAI's recent financials show a net loss of $53.5MM for 2Q23, with a cash reserve expected to last until mid-2024. Strategic financing negotiations are underway. We maintain a hold rating on ...Nasdaq provides company’s , which are financial statements and reports filed electronically with the U.S. Securities and Exchange Commission (SEC) by Quotemedia. The SEC requires all publicly ... Find the latest Institutional Holdings data for BioXcel Therapeutics, Inc. Common Stock (BTAI) at Nasdaq.com.

Shares of the commercial-stage biopharma BioXcel Therapeutics ( BTAI -2.02%) were up by 10.3% on heavy volume as of 3:29 p.m. ET Monday afternoon. The big gain came after the drugmaker reported ...Allogene Therapeutics (NASDAQ:) is a clinical-stage biotech firm specializing in developing allogeneic T cell cancer treatment therapies. Around 67.4% of ALLO’s share count consists of publicly ...

OnkosXcel is a subsidiary of BioXcel Therapeutics, Inc. (Nasdaq: BTAI). This press release is being made pursuant to, and in accordance with, Rule 135 under the Securities Act of 1933, ...BioXcel Therapeutics, Inc. (BTAI.NASDAQ) : Stock quote, stock chart, quotes, analysis, advice, financials and news for Stock BioXcel Therapeutics, ...

NEW HAVEN, Conn., Feb. 23, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative ...Nov 8, 2023 · AI. BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence, or AI, techniques. BioXcel Therapeutics, Inc. Common Stock (BTAI). Nasdaq Listed ...BTAI BTAI AFTER HOURS QUOTE BTAI LATEST AFTER HOURS TRADES. ... Add symbols now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing Stocks, Funds, ... Nov 14, 2022 · By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT Business Update Commercial Day Highlights Positive Early Launch Metrics for IGALMI™ On October 18, 2022, BioXcel Therapeutics ...

More specifically, Citadel Investment Group was the largest shareholder of BioXcel Therapeutics, Inc. (NASDAQ:BTAI), with a stake worth $32.5 million reported as of the end of September.

NEW HAVEN, Conn., April 26, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...

The Panera Bread Company is a public company that is traded on the NASDAQ stock market. The majority of its shareholders are financial institutions and mutual fund holders. The remaining shares are owned by direct holders of Panera Bread st...Over the past 3 months, 10 analysts have published their opinion on BioXcel Therapeutics (NASDAQ:BTAI) stock. These analysts are typically employed by large Wall Street banks and tasked with ...NEW HAVEN, Conn., May 11, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...BioXcel Therapeutics, Inc. (Nasdaq: BTAI) to host virtual Neuroscience R&D Day to discuss BXCL502, a potential treatment for chronic agitation in dementia, along with other emerging pipeline candidates. Dr. Jeffrey Cummings and Dr. Sandra Comer to discuss agitation relief in Alzheimer’s disease and BXCL501 as a potential treatment for opioid …NEW HAVEN, Conn., June 23, 2020 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...Alliancebernstein Now Owns 0.10% of BioXcel Therapeutics (BTAI) Feb 9, 2023.

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) recently conducted a meeting with the FDA regarding the development pathway for BXCL501 for the treatment of agitation associated with Alzheimer’s disease (AD). Following receipt of the meeting minutes, the company announced that it was aligned with the FDA’s recommendation to conduct an …If you’re familiar with investing, then you’ve probably heard of major stock exchanges like the New York Stock Exchange or the NASDAQ. Stock exchanges are sort of like a mixture between an auction house and a marketplace where investors can...Apr 28, 2023 · 586,279. 6.770742. Back to BTAI Overview. NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on mid-month and end ... HC Wainwright Lowers Price Target on BioXcel Therapeutics to $11 From $60, Maintains Buy Rating. Aug. 18. MT. UBS Adjusts BioXcel Therapeutics Price Target …Find the latest BioXcel Therapeutics, Inc. (BTAI) stock quote, history, news and other vital information to help you with your stock trading and investing.BioXcel Therapeutics, Inc. (NASDAQ:BTAI) dropped 21.2% to settle at $27.21 after Goldman Sachs downgraded the stock from Buy to Sell and lowered its price target from $55 to $24.

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q3 2023 Earnings Call Transcript November 14, 2023 BioXcel Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-1.72 EPS, expectations ...BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. The Company’s drug re-innovation ...

Based on analysts offering 12 month price targets for BTAI in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 .BioXcel Therapeutics (NASDAQ: BTAI) stock is plummeting Monday. The clinical-stage biotech specialist's share price is down 44.6% as of 11:15 a.m. ET, according to data from S&P Global Market ...Nov 7, 2023 · In the last trading session, 7.87 million shares of the BioXcel Therapeutics Inc (NASDAQ:BTAI) were traded, and its beta was 0.87. Most recently the company’s share price was $4.79, and it changed around $0.15 or 3.23% from the last close, which brings the market valuation of the company to $140.20M. BTAI currently trades at a discount to its ... Investors, who purchased BioXcel Therapeutics, Inc. (NASDAQ: BTAI) shares prior to December 2021 and continue to hold any of those NASDAQ: BTAI shares, also have certain options and should contact ...NEW HAVEN, Conn., March 03, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...Find the latest SEC Filings data for BioXcel Therapeutics, Inc. Common Stock (BTAI) at Nasdaq.com.The consensus among . 5 Wall Street analysts covering (NASDAQ: BTAI) stock is to Buy BTAI stock. Out of 5 analysts , 2 ( 40% ) are recommending BTAI as a Strong Buy, 1 ( 20% ) are recommending BTAI as a Buy, 2 ( 40% ) are recommending BTAI as a Hold, 0 ( 0% ) are recommending BTAI as a Sell, and 0 ( 0% ) are recommending BTAI as a Strong Sell.BioXcel Therapeutics, Inc. (BTAI) NasdaqCM - NasdaqCM Real Time Price. Currency in USD. Follow. 2W 10W 9M. 3.9000 +0.0700 (+1.83%) At close: 04:00PM EST. 3.9999 +0.10 (+2.56%) After hours:...Find the latest Earnings Report Date for BioXcel Therapeutics, Inc. Common Stock (BTAI) at Nasdaq.com.BioXcel Therapeutics saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 5,080,000 shares, a decrease of 12.6% from the previous total of 5,810,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a …

Find the latest SEC Filings data for BioXcel Therapeutics, Inc. Common Stock (BTAI) at Nasdaq.com.

BioXcel Therapeutics (NASDAQ: BTAI) is another of the low-float, heavily-shorted penny stocks in the biotech space. Based on its “about us” page, BioXcel is riding the coattails of “AI Mania ...BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. The Company’s drug re-innovation ...Based on analysts offering 12 month price targets for BTAI in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 .NEW HAVEN, Conn., July 19, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), today announced that Dr. Vimal Mehta, Ph.D., Founder and Chief Executive ...Nov 30, 2023 · Philadelphia, Pennsylvania--(Newsfile Corp. - November 29, 2023) - A recently filed securities fraud class action complaint alleges that BioXcel Therapeutics Inc. (NASDAQ: BTAI), via certain ... NEW HAVEN, Conn., Oct. 27, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative ...BioXcel Therapeutics (NASDAQ: BTAI) stock is plummeting Monday. The clinical-stage biotech specialist's share price is down 44.6% as of 11:15 a.m. ET, according to data from S&P Global Market ...BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. The Company’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning ...14 Aug 2023 ... Shares of the biopharmaceutical company, BioXcel Therapeutics (NASDAQ: BTAI) tanked at the time of writing on Monday after the company ...BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q3 2023 Earnings Call Transcript November 14, 2023 BioXcel Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-1.72 EPS, expectations ...View the latest BioXcel Therapeutics Inc. (BTAI) stock price, news, historical charts, analyst ratings and financial information from WSJ. NEW HAVEN, Conn., Jan. 05, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial ...

BioXcel Therapeutics Stock (NASDAQ:BTAI), Short Interest Report. Short interest for BioXcel Therapeutics gives investors a sense of the degree to which investors are betting on the decline of ... Nov 6, 2023 · BioXcel Therapeutics, Inc. (Nasdaq: BTAI) is a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience. The Company’s drug re-innovation ... BioXcel Therapeutics to host conference call today at 8:00 a.m. ET. NEW HAVEN, Conn., June 29, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company ...BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced the appointment of Michael P. Miller to its Board of Directors, effective July 1, 2022. Mr.Instagram:https://instagram. afghanistan povertyishares tltground floor reviewmeta 5 brokers NEW HAVEN, Conn., Feb. 23, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative ... amazon cryptocurrencystocks to buy on the dip NEW HAVEN, Conn., April 19, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI) (the “Company” or “BioXcel Therapeutics”), a commercial-stage biopharmaceutical company ... shell share value BTAI - Stock Quotes for BTAI Ent Holdg, NASDAQ: BTAI Stock Options Chain, Prices and News - Webull MARKET BTAI BTAI Bioxcel Therapeutics Inc NASDAQ 3.772 -0.028 …NEW HAVEN, Conn., Sept. 04, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company utilizing ...Nov 20, 2023 · BioXcel Therapeutics Inc (NASDAQ:BTAI) trade information. Instantly BTAI was in red as seen at the end of in last trading. With action -20.12%, the performance over the past five days has been red. The drop to weekly highs of 5.62 on Friday, 11/17/23 subtracted -2.82% to the stock’s daily price.